Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy
NCT ID: NCT03391830
Last Updated: 2021-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
250 participants
INTERVENTIONAL
2018-01-15
2020-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ameliorating Contrast Induced Nephropathy After Coronary Angiography
NCT06139952
N-Acetyl Cystein and Contrast Nephropathy
NCT01820195
Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.
NCT03867994
The Acetylcysteine for Contrast-Induced Nephropathy Trial
NCT00736866
Folic Acid for Prevention of Contrast Induced Nephropathy
NCT02444013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin-Ascorbic acid
atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
Atorvastatin-Ascorbic acid
atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
Placebo
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin-Ascorbic acid
atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Statin naive, or not on statin treatment for at least 14 day
Exclusion Criteria
* History of rhabdomyolysis or elevated creatinine kinase
* History of iodinated CM use within 14 days before randomization
* History of N-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure.
* History of hypersensitivity reaction to contrast media
* Pregnancy or lactation
* Acute renal failure
* End-stage renal disease requiring dialysis
* Cardiogenic shock or pulmonary edema
* Multiple myeloma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abdelwahab Hashem
Clinical Uro-oncology Fellow - Urology and Nephrology Center - Mansoura
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yasser Othman, MD
Role: STUDY_CHAIR
Urology and nephrology center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology and Nephrology Center
Al Mansurah, Aldakahlia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN PREVENTION
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.